Kwality Pharma Reports Positive Q2 Results, Operating Profit Ratio at 5-Year High

Kwality Pharmaceuticals, a microcap company in the pharmaceuticals and drugs industry, has recently announced its financial results for the quarter ending September 2024. The company's stock has been given a 'Hold' call by MarketsMOJO. According to the financial report, Kwality Pharma has shown a positive performance in the second quarter of the fiscal year 2024-2025. The company's score has improved from 11 to 17 in the last three months. One of the key factors contributing to this improvement is the company's operating profit to interest ratio, which is at its highest in the last five quarters at 7.25 times. This indicates that Kwality Pharma is effectively managing its interest payments. The company's profit before tax (PBT) less other income has also shown a significant growth of 55.29% year on year, reaching Rs 12.33 crore. This trend is expected to continue in the near future. Kwality Pharma's net sales have also seen a positive growth of 29.26% year on year, reaching Rs 90.03 crore. This indicates a positive trend in the company's sales performance. Moreover, the company's profit after tax (PAT) has also shown a growth of 35.7% year on year, reaching Rs 8.47 crore. This trend is expected to continue in the near future. The earnings per share (EPS) for the quarter have also reached its highest at Rs 8.16 in the last five quarters. This indicates an increasing profitability and higher earnings for shareholders. Overall, Kwality Pharmaceuticals has shown a strong financial performance in the quarter ending September 2024, with positive trends in key financial indicators. Investors are advised to hold their stocks in the company for now, as per the recommendation by MarketsMOJO.